Live intraday price
Compare with our price levels
Close 2026-09-30: $300.25 · Levels are calculated once a day from the closing price; live prices come from TradingView (may be delayed at times)
Price pulled back into the buy zone (E1) · 2 whales recently bought
🎯 Trade plan by price level
Buy in 3 tranches in the buy zone · sell in 3 tranches at the targets · sell everything if the stop-loss breaks
Price levels and picks are calculated automatically with the same formula for every stock — for education only, not a recommendation to buy or sell. · How it's calculated
Risk : reward 1 : 1.9Moves ~$7.50 a day
⚖️ Positives and risks
- ●2 whales bought or added last quarter
- ●Price pulled back to entry E1 (support)
- ●Average analyst price target 369.25 (upside +23%, 12 analysts)
- ●Most analysts rate it Buy
- ●Long-term downtrend (below a falling MA200)
- ●Lagged the market (S&P 500) by -22% over 6 months
- ●High debt: D/E 447%
🕯️ Price chart
Green lines = buy zone E1–E3 · orange = targets T1–T3 · red = stop-loss · arrows = where the paper-trading bot bought/sold
🐋 Whales holding this stock
From each whale's latest quarterly filing
👔 Insider buying & selling
Latest trades from SEC Form 4 filings
GREENBERG LON R · Director
2026-09-16 · 1,280 shares @ $321.30
Krikorian Lazarus · Officer
2026-09-01 · 985 shares @ $325.97 · pre-planned sale (10b5-1)
Campbell Elizabeth S · President
2026-08-24 · 11,300 shares @ $324.12
Tyler Lauren M · Director
2026-06-22 · 550 shares @ $270.23
DURCAN DERMOT MARK · Director
2026-06-18 · 4,000 shares @ $274.19
DURCAN DERMOT MARK · Director
2026-05-28 · 4,000 shares @ $266.26
Mauch Robert P. · CEO · Director
2026-02-20 · 3,762 shares @ $358.94 · pre-planned sale (10b5-1)
Mauch Robert P. · CEO · Director
2026-02-18 · 1,333 shares @ $359.46 · pre-planned sale (10b5-1)
Mauch Robert P. · CEO · Director
2026-01-20 · 5,096 shares @ $354.73 · pre-planned sale (10b5-1)
Campbell Elizabeth S · President
2025-12-19 · 3,351 shares @ $342.10
Battaglia Silvana · President
2025-12-19 · 1,677 shares @ $345.00
Mauch Robert P. · CEO · Director
2025-12-18 · 5,096 shares @ $343.45 · pre-planned sale (10b5-1)
Krikorian Lazarus · Officer
2025-12-17 · 4,031 shares @ $343.24
Mauch Robert P. · CEO · Director
2025-11-18 · 5,096 shares @ $366.64 · pre-planned sale (10b5-1)
Mauch Robert P. · CEO · Director
2025-10-20 · 5,097 shares @ $326.80 · pre-planned sale (10b5-1)
📊 Past earnings and price reaction
Actual EPS vs. analyst estimates · the price move on the first trading day after the report and over the next 20 trading days
Actual EPS $4.48 · est. $4.35 · Before open
Day 1
Next 20 days
Actual EPS $4.75 · est. $4.72 · Before open
Day 1
Next 20 days
Actual EPS $4.08 · est. $4.04 · Before open
Day 1
Next 20 days
Actual EPS $3.84 · est. $3.79 · Before open
Day 1
Next 20 days
Actual EPS $4.00 · est. $3.84 · Before open
Day 1
Next 20 days
Actual EPS $4.42 · est. $4.10 · Before open
Day 1
Next 20 days
Actual EPS $3.73 · est. $3.52 · Before open
Day 1
Next 20 days
Actual EPS $3.34 · est. $3.23 · Before open
Day 1
Next 20 days
Listen to the earnings call or read the full report on COR's investor relations page ↗ · Earnings data from Yahoo Finance
💬 User reviews
Rate and review this stock (sign-in required) — reviews don't affect the system's scores
Loading…
Ratings and comments are each user's own opinion. They don't affect the Smart-Money Score, signals, or price levels and are not investment advice · The average counts each person's latest rating, one vote per person
📰 Latest news
1 of Wall Street’s Favorite Stocks with Impressive Fundamentals and 2 We Turn Down
StockStory · 2026-09-28
AbbVie vs. Pfizer: Which Healthcare Stock Makes Your Portfolio Healthier in 2026?
Motley Fool · 2026-09-25
AbbVie vs. Novo Nordisk: Which Drug Giant Stock Is a Better Buy in 2026?
Motley Fool · 2026-09-24
AbbVie vs. Eli Lilly: Which Star Pharma Stock Is a Better Buy in 2026?
Motley Fool · 2026-09-24
Can CAH's MSO Expansion Unlock Growth in Specialty Care Delivery?
Zacks · 2026-09-22
🔬 Deep dive
For those who want the detailed numbers